Scientists Sweden developed a simple and reliable method for diagnosing Alzheimer’s disease at the earliest stages, which should help more effectively treat patients. The disclosed approach includes blood test and three cognitive tests, the execution of which takes only 10 minutes. The accuracy of the new method is 90 percent. This is reported in the article published in the journal Nature Medicine.
340 patients from Sweden and 543 patients from North America with light memory violations took part in the study. Specialists estimated the level of such biomarkers of Alzheimer’s disease as phosphorylated Tau-protein in the blood plasma, the ratio of two forms of Beta-amyloid Aβ42 (in the aminoxylota chains 42) and Aβ40 (40 amino acids), a thin polypeptide neurofilament in a plasma associated with Alzheimer’s disease. APOE GENER .
The identification of Tau-protein in the blood plasma by 83 percent accurately predicted the initial stage of Alzheimer’s disease over the next four years. Combined with the results of the test on the cognitive abilities of the APOE analysis, the forecast has improved up to 90 percent.
According to Neurobiologist Oskar Hanson (Oskar Hansson) from the University of Lund in Sweden, the algorithm allows for clinical trials of people with early manifestations of Alzheimer’s disease, when new drugs have more chances to slow down neurodegenerative progression. It also allows you to identify a dangerous disease where there is no possibility for more expensive procedures, including the visualization of the brain or the analysis of the spinal fluid.
According to the World Health Organization (WHO), currently about 50 million people with dementia are currently in the world, and almost 10 million new cases occur annually. The most common form of dementia is incurable so far Alzheimer’s disease, which accounts for 60-70 percent of all cases.